NEURONET will boost synergy and collaboration across IMI’s projects in neurodegenerative disorders

The Innovative Medicines Initiative (IMI) has recently launched the project NEURONET: Efficiently Networking European Neurodegeneration Research. Dr José Luis Molinuevo, scientific director of the Alzheimer’s Prevention Program at BarcelonaBeta Brain Research Center (BBRC), has been elected representative of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project at the NEURONET Scientific Coordination Board. 

The aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders portfolio, such as AMYPAD and EPAD, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide. 

The project is composed of 9 partners from EFPIA companies, public bodies, small companies and patient organizations. It will last 3 years and it is funded with 2,3M euros under grant agreement number 821513.

Dr Molinuevo is a member of the AMYPAD’s Executive Committee and leads a work package whose mission is to focus on understanding the natural history of Alzheimer’s disease, defining the window for intervention and trial-readiness population in conjunction with EPAD’s protocol for the Longitudinal Cohort Study.